JP6259463B2 - ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用であるアルキルアミド置換ピリジル化合物 - Google Patents
ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用であるアルキルアミド置換ピリジル化合物 Download PDFInfo
- Publication number
- JP6259463B2 JP6259463B2 JP2015541882A JP2015541882A JP6259463B2 JP 6259463 B2 JP6259463 B2 JP 6259463B2 JP 2015541882 A JP2015541882 A JP 2015541882A JP 2015541882 A JP2015541882 A JP 2015541882A JP 6259463 B2 JP6259463 B2 JP 6259463B2
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- mmol
- alkyl
- membered
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Dermatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723854P | 2012-11-08 | 2012-11-08 | |
| US61/723,854 | 2012-11-08 | ||
| PCT/US2013/068842 WO2014074660A1 (en) | 2012-11-08 | 2013-11-07 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506368A JP2016506368A (ja) | 2016-03-03 |
| JP2016506368A5 JP2016506368A5 (enExample) | 2016-11-17 |
| JP6259463B2 true JP6259463B2 (ja) | 2018-01-10 |
Family
ID=49667568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015541882A Active JP6259463B2 (ja) | 2012-11-08 | 2013-11-07 | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用であるアルキルアミド置換ピリジル化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9315494B2 (enExample) |
| EP (1) | EP2922841B8 (enExample) |
| JP (1) | JP6259463B2 (enExample) |
| KR (1) | KR102233252B1 (enExample) |
| CN (1) | CN104781252B (enExample) |
| AR (1) | AR093403A1 (enExample) |
| AU (1) | AU2013341185B2 (enExample) |
| BR (1) | BR112015010244A8 (enExample) |
| CA (1) | CA2890929A1 (enExample) |
| EA (1) | EA028526B1 (enExample) |
| IL (1) | IL238554A0 (enExample) |
| MX (1) | MX2015005272A (enExample) |
| SG (1) | SG11201503396UA (enExample) |
| TW (1) | TWI620737B (enExample) |
| WO (1) | WO2014074660A1 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2890935A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha. |
| PT2922846T (pt) | 2012-11-08 | 2018-12-19 | Bristol Myers Squibb Co | Compostos heterocíclicos substituídos por amida úteis como moduladores de il-12, il-23 e/ou ie'n-alfa |
| CA2890983A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
| AR094537A1 (es) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| ES2702126T3 (es) | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| TW201609693A (zh) | 2014-01-03 | 2016-03-16 | 必治妥美雅史谷比公司 | 雜芳基取代之菸鹼醯胺化合物 |
| WO2016001341A1 (en) * | 2014-07-03 | 2016-01-07 | F. Hoffmann-La Roche Ag | Sulfonylaminopyridine compounds, compositions and methods of use |
| WO2016022626A1 (en) * | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| CN107849039B (zh) | 2015-06-24 | 2020-07-03 | 百时美施贵宝公司 | 经杂芳基取代的氨基吡啶化合物 |
| TW201713663A (zh) | 2015-06-24 | 2017-04-16 | 必治妥美雅史谷比公司 | 經雜芳基取代之胺基吡啶化合物 |
| KR102641263B1 (ko) | 2015-06-24 | 2024-02-26 | 브리스톨-마이어스 스큅 컴퍼니 | 헤테로아릴 치환된 아미노피리딘 화합물 |
| MX379776B (es) * | 2015-11-26 | 2025-03-11 | Novartis Ag | Derivados de diamino piridina para usarse en el tratamiento de dermatitis atópica o psoriasis. |
| JP7082130B2 (ja) | 2016-10-14 | 2022-06-07 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| AU2017345736B2 (en) | 2016-10-21 | 2022-04-07 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| AR110351A1 (es) * | 2016-12-13 | 2019-03-20 | Bristol Myers Squibb Co | COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| EP4338802A3 (en) | 2017-03-08 | 2024-09-04 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors, uses, and methods for production thereof |
| US10829496B2 (en) | 2017-05-11 | 2020-11-10 | Bristol-Myers Squibb Company | Thienopyridines and benzothiophenes useful as IRAK4 inhibitors |
| TWI776810B (zh) * | 2017-05-12 | 2022-09-11 | 瑞士商諾華公司 | 新穎二胺基吡啶衍生物 |
| CN111194317A (zh) | 2017-07-28 | 2020-05-22 | 林伯士拉克许米公司 | Tyk2抑制剂与其用途 |
| EP3713930A1 (en) * | 2017-11-21 | 2020-09-30 | Bristol-Myers Squibb Company | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019160875A1 (en) | 2018-02-13 | 2019-08-22 | Rutgers, The State University Of New Jersey | Antibacterial agents: soluble salts and aqueous formulations of pyronins |
| WO2019160873A1 (en) | 2018-02-13 | 2019-08-22 | Rutgers, The State University Of New Jersey | Antibacterial agents: o-alkyl-deuterated pyronins |
| US11572337B2 (en) | 2018-03-06 | 2023-02-07 | Rutgers, The State University Of New Jersey | Antibacterial agents: arylalkylcarboxamido phloroglucinols |
| JP6557436B1 (ja) | 2018-03-12 | 2019-08-07 | アッヴィ・インコーポレイテッド | チロシンキナーゼ２媒介性シグナル伝達の阻害剤 |
| KR102741437B1 (ko) * | 2018-03-22 | 2024-12-10 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 피리딘을 포함하는 헤테로시클릭 화합물 |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| CN113271940A (zh) | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| KR102858043B1 (ko) * | 2018-10-30 | 2025-09-10 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물 |
| KR102891608B1 (ko) | 2018-11-30 | 2025-11-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| WO2020112937A1 (en) | 2018-11-30 | 2020-06-04 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| WO2020154474A1 (en) | 2019-01-23 | 2020-07-30 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| CN115448910B (zh) * | 2019-01-28 | 2024-04-19 | 江苏豪森药业集团有限公司 | 一种哒嗪类衍生物抑制剂、其制备方法和应用 |
| KR20220035447A (ko) | 2019-07-18 | 2022-03-22 | 브리스톨-마이어스 스큅 컴퍼니 | IRAK4 억제제로서 유용한 피라졸로[3,4-d]피롤로[1,2-b]피리다지닐 화합물 |
| WO2021011724A1 (en) | 2019-07-18 | 2021-01-21 | Bristol-Myers Squibb Company | Tricyclic heteroaryl compounds useful as irak4 inhibitors |
| US12304916B2 (en) | 2019-07-23 | 2025-05-20 | Bristol-Myers Squibb Company | Thienopyridinyl and thiazolopyridinyl compounds useful as IRAK4 inhibitors |
| ES2983263T3 (es) | 2019-08-06 | 2024-10-22 | Bristol Myers Squibb Co | Compuestos heterocíclicos bicíclicos útiles como inhibidores de IRAK4 |
| MX2022002877A (es) | 2019-09-13 | 2022-08-08 | Nimbus Saturn Inc | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos. |
| US12391702B2 (en) | 2020-02-03 | 2025-08-19 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors |
| WO2021158498A1 (en) | 2020-02-03 | 2021-08-12 | Bristol-Myers Squibb Company | Tricyclic heteroaryl compounds useful as irak4 inhibitors |
| US20220330549A1 (en) * | 2020-03-11 | 2022-10-20 | Northwest A&F University | Use of n-benzylbenzamide-based compound as herbicide |
| CN115702145A (zh) * | 2020-04-14 | 2023-02-14 | 戈萨默生物服务公司 | 用于治疗炎性疾病的取代的吡啶 |
| WO2021222153A1 (en) * | 2020-04-28 | 2021-11-04 | Bristol-Myers Squibb Company | Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators |
| KR20230038740A (ko) * | 2020-08-07 | 2023-03-21 | 파마블럭 사이언시스 (난징), 인코포레이티드 | Cdk9 억제제 및 이의 용도 |
| CN114181257B (zh) * | 2020-09-14 | 2025-02-14 | 四川科伦博泰生物医药股份有限公司 | 吡啶类化合物，包含其的药物组合物，其制备方法及其用途 |
| JP2023546996A (ja) | 2020-10-23 | 2023-11-08 | ニンバス クロソー， インコーポレイテッド | Ｃｔｐｓ１阻害剤およびその使用 |
| US20240076285A1 (en) * | 2020-12-16 | 2024-03-07 | Shankar Venkatraman | Compounds and compositions for treating conditions associated with sting activity |
| CN116867758A (zh) | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| CA3206501A1 (en) | 2021-02-02 | 2022-08-11 | Shaun Abbott | Gpr84 antagonists and uses thereof |
| EP4288430A1 (en) | 2021-02-02 | 2023-12-13 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| US12252488B2 (en) | 2021-02-12 | 2025-03-18 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| MX2023009527A (es) | 2021-02-15 | 2023-08-24 | Kymera Therapeutics Inc | Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos. |
| WO2022175747A1 (en) | 2021-02-19 | 2022-08-25 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| WO2022175745A1 (en) * | 2021-02-19 | 2022-08-25 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| KR20230159421A (ko) * | 2021-02-19 | 2023-11-21 | 수도 바이오사이언시즈 리미티드 | Tyk2 억제제 및 이의 용도 |
| BR112023016678A2 (pt) * | 2021-02-19 | 2023-11-14 | Sudo Biosciences Ltd | Inibidores de tyk2 e usos dos mesmos |
| US11926625B2 (en) | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| JP2024513011A (ja) | 2021-03-29 | 2024-03-21 | ニンバス サターン， インコーポレイテッド | Ｈｐｋ１アンタゴニスト及びその使用 |
| WO2022217276A1 (en) | 2021-04-09 | 2022-10-13 | Nimbus Clio, Inc. | Cbl-b modulators and uses thereof |
| WO2023076161A1 (en) | 2021-10-25 | 2023-05-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| IL312397A (en) | 2021-10-29 | 2024-06-01 | Kymera Therapeutics Inc | IRAK4 subunits and their synthesis |
| WO2023108536A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
| JP2025503448A (ja) | 2021-12-16 | 2025-02-04 | リンク ファーマシューティカルズ シーオー．エルティーディー． | Ｔｙｋ２阻害剤および組成物ならびにその方法 |
| US12091411B2 (en) | 2022-01-31 | 2024-09-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| CN116693449A (zh) | 2022-03-04 | 2023-09-05 | 上海致根医药科技有限公司 | 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用 |
| CN119585250A (zh) * | 2022-04-19 | 2025-03-07 | 蓝图药品公司 | Kit抑制剂 |
| WO2023227946A1 (en) * | 2022-05-27 | 2023-11-30 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| IL318576A (en) | 2022-08-02 | 2025-03-01 | Liminal Biosciences Ltd | Pyridoxine-substituted GPR84 antagonists and their uses |
| AU2023317740A1 (en) | 2022-08-02 | 2025-03-13 | Liminal Biosciences Limited | Heteroaryl carboxamide and related gpr84 antagonists and uses thereof |
| KR20250057801A (ko) | 2022-08-02 | 2025-04-29 | 리미널 바이오사이언시스 리미티드 | 아릴-트라이아졸릴 및 관련 gpr84 길항제 및 이의 용도 |
| WO2024249855A1 (en) * | 2023-06-02 | 2024-12-05 | Idrx, Inc. | Combination therapy comprising kit inhibitors for use in the treatment of cancer |
| WO2025062372A1 (en) | 2023-09-21 | 2025-03-27 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors for use in the treatment of inflammatory bowel disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| GB0719644D0 (en) * | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2010058846A1 (ja) * | 2008-11-21 | 2010-05-27 | アステラス製薬株式会社 | ４，６-ジアミノニコチンアミド化合物 |
| WO2012062704A1 (en) * | 2010-11-09 | 2012-05-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
-
2013
- 2013-11-07 AR ARP130104094A patent/AR093403A1/es unknown
- 2013-11-07 AU AU2013341185A patent/AU2013341185B2/en not_active Ceased
- 2013-11-07 EA EA201590913A patent/EA028526B1/ru not_active IP Right Cessation
- 2013-11-07 JP JP2015541882A patent/JP6259463B2/ja active Active
- 2013-11-07 CA CA2890929A patent/CA2890929A1/en not_active Abandoned
- 2013-11-07 BR BR112015010244A patent/BR112015010244A8/pt not_active Application Discontinuation
- 2013-11-07 WO PCT/US2013/068842 patent/WO2014074660A1/en not_active Ceased
- 2013-11-07 KR KR1020157014693A patent/KR102233252B1/ko not_active Expired - Fee Related
- 2013-11-07 CN CN201380058022.7A patent/CN104781252B/zh active Active
- 2013-11-07 SG SG11201503396UA patent/SG11201503396UA/en unknown
- 2013-11-07 US US14/441,193 patent/US9315494B2/en active Active
- 2013-11-07 MX MX2015005272A patent/MX2015005272A/es unknown
- 2013-11-07 TW TW102140570A patent/TWI620737B/zh not_active IP Right Cessation
- 2013-11-07 EP EP13795911.0A patent/EP2922841B8/en active Active
-
2015
- 2015-04-30 IL IL238554A patent/IL238554A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014074660A1 (en) | 2014-05-15 |
| IL238554A0 (en) | 2015-06-30 |
| KR102233252B1 (ko) | 2021-03-26 |
| AU2013341185A1 (en) | 2015-07-02 |
| AR093403A1 (es) | 2015-06-03 |
| EP2922841A1 (en) | 2015-09-30 |
| EP2922841B1 (en) | 2017-06-07 |
| TW201422587A (zh) | 2014-06-16 |
| SG11201503396UA (en) | 2015-05-28 |
| JP2016506368A (ja) | 2016-03-03 |
| CA2890929A1 (en) | 2014-05-15 |
| TWI620737B (zh) | 2018-04-11 |
| AU2013341185B2 (en) | 2017-07-13 |
| BR112015010244A2 (pt) | 2017-07-11 |
| EA201590913A1 (ru) | 2015-10-30 |
| CN104781252B (zh) | 2017-11-17 |
| EP2922841B8 (en) | 2017-08-02 |
| CN104781252A (zh) | 2015-07-15 |
| MX2015005272A (es) | 2015-07-14 |
| KR20150081338A (ko) | 2015-07-13 |
| BR112015010244A8 (pt) | 2019-10-01 |
| EA028526B1 (ru) | 2017-11-30 |
| US9315494B2 (en) | 2016-04-19 |
| US20150307483A1 (en) | 2015-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6259463B2 (ja) | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用であるアルキルアミド置換ピリジル化合物 | |
| JP6585231B2 (ja) | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なアミド置換ヘテロ環式化合物 | |
| US9987266B2 (en) | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | |
| HK1226400B (en) | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150805 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160928 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160928 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170817 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170822 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20171004 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171116 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171205 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171208 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6259463 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |